22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for biotechs...
20:49 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Fosun's biosimilar unit to raise $190M

Shanghai Henlius Biotech Inc. (Shanghai, China) said on Dec. 21, 2017, it will raise RMB1.3 billion ($192.5 million) through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company...
23:59 , Dec 28, 2017 |  BC Extra  |  Financial News

Fosun's biosimilar unit to raise $190M

On Dec. 20, Shanghai Henlius Biotech Inc. (Shanghai, China) said it will raise RMB1.3 billion ($192.5 million) through the sale of 55.4 million shares at RMB22.71, including 14.6 million shares to its parent company Fosun...
21:20 , Nov 9, 2017 |  BC Innovations  |  Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...
20:12 , Sep 22, 2017 |  BC Week In Review  |  Financial News

AbClon raises W6.8B in IPO

On Sept. 18, AbClon Inc. (KOSDAQ:174900) raised W6.8 billion ($6.1 million) through the sale of 680,741 shares at W10,000 in an IPO. Director Kyu-Tae Kim told BioCentury that AbClon's lead candidate is AC101, a mAb targeting...
19:21 , Sep 19, 2017 |  BC Extra  |  Financial News

AbClon continues to rise after IPO

Korean biotech AbClon Inc. (KOSDAQ:174900) gained W4,050 (16%) to W30,050 in its second day of trading Tuesday. The closing price values the company at W204.4 billion ($183.9 million). On its first day of trading Monday, the...
07:00 , Oct 19, 2015 |  BioCentury  |  Strategy

Sourcing biologics in China

Eli Lilly and Co.'s decision to go back for seconds with Chinese biotech Innovent Biologics Inc. illustrates a turning tide in a country not historically known for either innovative biologics or manufacturing quality. Last week...
07:00 , Mar 10, 2014 |  BioCentury  |  Emerging Company Profile

JHL: Biomanufacturing solar system

JHL Biotech Inc. aims to build a network of R&D and manufacturing facilities across Asia to develop, manufacture and commercialize affordable, high-quality biologics that meet international standards. The company is developing an internal pipeline of...
07:00 , Mar 18, 2013 |  BioCentury  |  Product Development

Bettering China's biosimilars

While many homegrown biologics marketed in China could be perceived as biosimilars, most are unlikely to meet international standards and are not marketed as such in China. But with an uptick in returnees and VC...